HealthIT Answers August 28, 2024
By Kim Boyd, Regulatory Resource Center Lead & Senior Consultant, Point-of-Care Partners
In an era where data fluidity is transforming healthcare, life sciences manufacturers must stay attuned to evolving Health IT policies given that many of these policies have downstream effects on life sciences and access to expanded deidentified and aggregated datasets. The proposed HTI-2 rule is a critical piece of this transformation, offering profound implications for the industry. Here’s why life sciences companies should monitor this rule and consider engaging by submitting comments (Due October 4, 2024).
Real-Time Prescription Benefit (RTPB) Certification: A Market Access Opportunity
The HTI-2 rule proposes the certification of Real-Time Prescription Benefit (RTPB) standards, which is a game-changer for patients’ access to their needed therapies....
Today's Sponsors
Today's Sponsor